X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

Posted: January 27, 2025 at 2:49 am

Submission supported by positive results from global, Phase 3 4WHIM clinical trial;

View post:
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

Related Posts